Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Neuromyelitis optica is a relapsing inflammatory disorder of the central nervous system that manifests predominantly with attacks of optic neuritis and longitudinally extensive transverse myelitis; attacks are often severe. In contrast to multiple sclerosis, a secondary progressive phase is rare, and disability in neuromyelitis optica spectrum disorders is related to relapses. Thus, prompt and effective treatment of relapses, and early initiation of long-term immunosuppression to prevent subsequent attacks is required in order to prevent morbidity and mortality.

Original publication

DOI

10.1586/14737175.2016.1150178

Type

Journal article

Journal

Expert Rev Neurother

Publication Date

2016

Volume

16

Pages

319 - 329

Keywords

AQP4-Ab, NMO, NMOSD, Neuromyelitis optica, aquaporin-4, neuromyelitis optica spectrum disorders, treatment, Humans, Immunosuppressive Agents, Neuromyelitis Optica